文献速递血栓与止血

肿瘤血栓患者的管理与结局:一项回顾性队列研究

Management and outcomes in patients with tumor thrombus: a retrospective cohort study.
PubMed 文献 · J Thromb Haemost · 2024-10-12

该单中心回顾性队列纳入2019至2022年211例肿瘤血栓患者,随访12个月。50.2%接受抗凝治疗,12个月新发静脉血栓栓塞症(VTE)累积发生率为11.4%,大出血+临床相关非大出血为36.6%,死亡率为52.5%,抗凝组与未抗凝组间无显著差异。

要点

  • 肿瘤血栓患者12个月新发VTE累积发生率为11.4%(95%CI 7.3%-16.5%)。
  • 12个月大出血+临床相关非大出血累积发生率为36.6%(95%CI 29.6%-43.5%)。
  • 12个月死亡率为52.5%(95%CI 44.8%-59.6%),抗凝组与未抗凝组无显著差异。

核心结论

  • 肿瘤血栓患者携带高VTE、出血和死亡风险。
  • 抗凝治疗的影响仍不明确。

研究设计与样本

  • 单中心回顾性队列研究,纳入2019至2022年肿瘤血栓患者。
  • 共纳入211例患者,从肿瘤血栓诊断起随访12个月或至死亡(若死亡更早)。
  • 主要结局为因肿瘤血栓(或并发无血栓性血栓/VTE)接受任何剂量抗凝治疗的患者百分比。
  • 次要结局包括新发血栓形成、大出血、临床相关非大出血和死亡率;以死亡为竞争风险计算6个月和12个月累积发生率及95%CI,并比较抗凝组与未抗凝组。

主要发现

  • 211例患者中106例(50.2%;95%CI 47.9%-52.6%)因肿瘤血栓或并发VTE接受抗凝治疗,并发VTE见于21.8%。
  • 最常见癌症类型为肝细胞癌(28%),最常累及内脏静脉(49.3%)。
  • 肿瘤血栓累及下腔静脉和/或心脏、并发VTE或请血栓服务会诊时更可能使用抗凝。
  • 12个月新发VTE总体累积发生率为11.4%(95%CI 7.3%-16.5%),大出血+临床相关非大出血为36.6%(95%CI 29.6%-43.5%),死亡率为52.5%(95%CI 44.8%-59.6%)。
  • 抗凝组与未抗凝组上述结局无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumor thrombus can be associated with an increased risk of venous thromboembolism (VTE) and poor prognosis. The risks and benefits of anticoagulation remain unclear. OBJECTIVES: To evaluate the role of anticoagulation and associated outcomes in patients with tumor thrombus. METHODS: We conducted a single-center retrospective cohort study in patients with tumor thrombus from 2019 to 2022. All patients were followed for 12 months from the diagnosis of tumor thrombus or until death if death occurred earlier. The primary outcome was the percentage of patients prescribed any dose of anticoagulation for tumor thrombus (or concurrent bland thrombus/VTE). The secondary outcomes included new thrombosis, major bleeding, clinically relevant nonmajor bleeding, and mortality. We calculated the 6- and 12-month cumulative incidence of outcomes with 95% CI and compared those given anticoagulation vs not, considering death as a competing risk. RESULTS: We included 211 patients, among whom 106 (50.2%; 95% CI, 47.9%-52.6%) were given anticoagulation for tumor thrombus or concurrent VTE (present in 21.8%). The most common type of cancer was hepatocellular carcinoma (28%). Splanchnic veins were the most commonly involved (49.3%). Anticoagulation was more likely used if tumor thrombus involved the inferior vena cava and/or the heart, with concurrent VTE, or if thrombosis service was consulted. The overall 12-month incidence of new VTE was 11.4% (95% CI, 7.3%-16.5%), that of major bleeding + clinically relevant nonmajor bleeding was 36.6% (95% CI, 29.6%-43.5%), and mortality of 52.5% (95% CI, 44.8%-59.6%), with no significant differences among groups given anticoagulation or not. CONCLUSION: Patients with tumor thrombus carry high risks of VTE, bleeding, and mortality. The impact of anticoagulation remains unclear.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Hui S, Zeid K, Kou R, et al. Management and outcomes in patients with tumor thrombus: a retrospective cohort study. J Thromb Haemost. 2024. PMID: 39401736. doi:10.1016/j.jtha.2024.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。